Cargando…
Impact of SARS-CoV-2 omicron BA.1 and delta AY.4.2 variants on the neutralization by sera of patients treated with different authorized monoclonal antibodies
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8923034/ https://www.ncbi.nlm.nih.gov/pubmed/35304279 http://dx.doi.org/10.1016/j.cmi.2022.03.005 |
| _version_ | 1784669612681461760 |
|---|---|
| author | Dragoni, Filippo Schiaroli, Elisabetta Micheli, Valeria Fiaschi, Lia Lai, Alessia Zehender, Gianguglielmo Rossetti, Barbara Gismondo, Maria Rita Francisci, Daniela Zazzi, Maurizio Vicenti, Ilaria |
| author_facet | Dragoni, Filippo Schiaroli, Elisabetta Micheli, Valeria Fiaschi, Lia Lai, Alessia Zehender, Gianguglielmo Rossetti, Barbara Gismondo, Maria Rita Francisci, Daniela Zazzi, Maurizio Vicenti, Ilaria |
| author_sort | Dragoni, Filippo |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8923034 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-89230342022-03-15 Impact of SARS-CoV-2 omicron BA.1 and delta AY.4.2 variants on the neutralization by sera of patients treated with different authorized monoclonal antibodies Dragoni, Filippo Schiaroli, Elisabetta Micheli, Valeria Fiaschi, Lia Lai, Alessia Zehender, Gianguglielmo Rossetti, Barbara Gismondo, Maria Rita Francisci, Daniela Zazzi, Maurizio Vicenti, Ilaria Clin Microbiol Infect Letter to the Editor European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. 2022-07 2022-03-15 /pmc/articles/PMC8923034/ /pubmed/35304279 http://dx.doi.org/10.1016/j.cmi.2022.03.005 Text en © 2022 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Letter to the Editor Dragoni, Filippo Schiaroli, Elisabetta Micheli, Valeria Fiaschi, Lia Lai, Alessia Zehender, Gianguglielmo Rossetti, Barbara Gismondo, Maria Rita Francisci, Daniela Zazzi, Maurizio Vicenti, Ilaria Impact of SARS-CoV-2 omicron BA.1 and delta AY.4.2 variants on the neutralization by sera of patients treated with different authorized monoclonal antibodies |
| title | Impact of SARS-CoV-2 omicron BA.1 and delta AY.4.2 variants on the neutralization by sera of patients treated with different authorized monoclonal antibodies |
| title_full | Impact of SARS-CoV-2 omicron BA.1 and delta AY.4.2 variants on the neutralization by sera of patients treated with different authorized monoclonal antibodies |
| title_fullStr | Impact of SARS-CoV-2 omicron BA.1 and delta AY.4.2 variants on the neutralization by sera of patients treated with different authorized monoclonal antibodies |
| title_full_unstemmed | Impact of SARS-CoV-2 omicron BA.1 and delta AY.4.2 variants on the neutralization by sera of patients treated with different authorized monoclonal antibodies |
| title_short | Impact of SARS-CoV-2 omicron BA.1 and delta AY.4.2 variants on the neutralization by sera of patients treated with different authorized monoclonal antibodies |
| title_sort | impact of sars-cov-2 omicron ba.1 and delta ay.4.2 variants on the neutralization by sera of patients treated with different authorized monoclonal antibodies |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8923034/ https://www.ncbi.nlm.nih.gov/pubmed/35304279 http://dx.doi.org/10.1016/j.cmi.2022.03.005 |
| work_keys_str_mv | AT dragonifilippo impactofsarscov2omicronba1anddeltaay42variantsontheneutralizationbyseraofpatientstreatedwithdifferentauthorizedmonoclonalantibodies AT schiarolielisabetta impactofsarscov2omicronba1anddeltaay42variantsontheneutralizationbyseraofpatientstreatedwithdifferentauthorizedmonoclonalantibodies AT michelivaleria impactofsarscov2omicronba1anddeltaay42variantsontheneutralizationbyseraofpatientstreatedwithdifferentauthorizedmonoclonalantibodies AT fiaschilia impactofsarscov2omicronba1anddeltaay42variantsontheneutralizationbyseraofpatientstreatedwithdifferentauthorizedmonoclonalantibodies AT laialessia impactofsarscov2omicronba1anddeltaay42variantsontheneutralizationbyseraofpatientstreatedwithdifferentauthorizedmonoclonalantibodies AT zehendergianguglielmo impactofsarscov2omicronba1anddeltaay42variantsontheneutralizationbyseraofpatientstreatedwithdifferentauthorizedmonoclonalantibodies AT rossettibarbara impactofsarscov2omicronba1anddeltaay42variantsontheneutralizationbyseraofpatientstreatedwithdifferentauthorizedmonoclonalantibodies AT gismondomariarita impactofsarscov2omicronba1anddeltaay42variantsontheneutralizationbyseraofpatientstreatedwithdifferentauthorizedmonoclonalantibodies AT franciscidaniela impactofsarscov2omicronba1anddeltaay42variantsontheneutralizationbyseraofpatientstreatedwithdifferentauthorizedmonoclonalantibodies AT zazzimaurizio impactofsarscov2omicronba1anddeltaay42variantsontheneutralizationbyseraofpatientstreatedwithdifferentauthorizedmonoclonalantibodies AT vicentiilaria impactofsarscov2omicronba1anddeltaay42variantsontheneutralizationbyseraofpatientstreatedwithdifferentauthorizedmonoclonalantibodies |